Oral contraceptive therapy is associated with a fourfold increased risk of venous thromboembolism as compared with agematched non-users. The composition of oral contraceptives has varied considerably during the past two to three decades. The estrogen content (ethinylestradiol) has decreased and is now less than 0.03 mg/pill. This was done on the assumption that estrogen was the main culprit for thrombotic complications. Subsequently it was found that the progestins contained in the pill could also play a thrombogenic role. This was particularly maintained to be so for the third-generations progestins, namely gestodene or desogestrel. These gonane progestins have been widely used since the early 1990s, because they appeared to have a lesser androgenic effect. A careful and impartial evaluation of the literature seems to indicate that third-generation progestins are associated with a slight increase in thrombotic risk. However, the significance of this difference remains to be proven. In fact, a relative risk of only two in retrospective studies may have limited effect and disappear in prospectives studies. The role of associ-Address correspondence and reprint requests to
The association between oral contraceptives and venous thromboembolism is a well-established fact (1) (2) (3) (4) (5) .
Deep vein thrombosis may sometimes evolve into fatal or nonfatal pulmonary embolism. Approximately 30% of patients, especially if not properly and promptly treated, may experience a postphlebitic syndrome (6, 7) . This syndrome, with swelling, stasis, and discomfort, may be particularly troublesome for young women.
The nature of the specific defect induced by oral contraceptive preparations and responsible ated risk factors, both congenital and acquired, has been often overlooked in most of the papers dealing with the subject. This may be important. Preparations containing third-generation progestins are probably associated with a slight increase in thrombosis risk. It is the responsibility of the physician to select the preparation most suited for a given patient. As a general rule it may be safe to start with a preparation containing second-generation progestins. However there is no need for "a pill scare" and it does not seem justified to have women already taking pills containing third-generation progestins to switch to other preparations. If a woman taking preparations containing third-generation progestins experience symptoms, it is probably safe to advise that patient not to take any oral contraceptive pill in the future, regardless of the type. The same is true for women who experience symptoms while taking second-generation progestins preparations. Key Words: Estrogen-Oral contraceptives-Progestin-Venous thromboembolism.
for the thrombotic manifestations is still poorly defined. Antithrombin and free protein S are decreased in women taking oral contraceptives, along with an increase in factors II, VII, IX, and X. Experimental data suggest that these compounds induce a resistance to the activated protein C. An interference in the inactivation of endogenous thrombin and an inhibition of fibrinolysis may play a role. Overall, the changes seen to indicate a complex shift toward hypercoagulability (4, 8, 9) , and this multifactorial pathogenesis is probably the most likely explanation for the thrombotic complications. In other words, there may be no single culprit but a combination of several causes. This is more so when one takes into account the fact that women who show a contraceptive-associated venous thrombosis present often with associated risk factors, both con-genital and acquired (10) (11) (12) (13) . Antithrombin deficiency appears to be most dangerous condition in this regard (5) .
For physicians, there are multiple prescription choices (9, (14) (15) (16) (17) . This may vary from one country to the other but the main preparations available in Europe are: a) at least one preparation with norgestrel and ethinylestradiol, b) several preparations containing levonorgestrel and ethynilestradiol, c) several preparations containing desogestrel and ethinylestradiol, d) several preparations containing gestoden with ethinylestradiol, and e) at least one preparation containing cyproterone and ethinylestradiol. Some of the products containing gestoden or desogestrel (for example Gracial, Organon, and Minesse; Wyeth-Lederle) and variable amounts of ethinylestradiol have been introduced recently.
During 2000 and 2001, two new preparations containing levonorgestrel and 0.02-mg ethinylestradiol have been introduced. Because levonogestrel and gestodene are both considered thirdgeneration progestins or gonane progestins with approximately the same features, they can be unified in a single group. The compositions of all these preparations are gathered in Tables 1 to 3 .
The same pattern is probably true for other countries of the western world except for the occasional change in trademark names. In the United States, no preparation containing gestoden as a progestin is available. On the contrary there are preparations containing another progestin, namely norgestimate (e.g., Ortho Tricyclan). This progestin, rarely used in Europe, is usually classified as a third-generation progestin but this may be wrong because its main metabolite is norgestrel, which is a second-generation progestin. Because of this, patients receiving this compound should be eliminated from all studies comparing the effects of third-generation progestin to second-generation progestins. Alternatively the patients should be pooled with data pertaining to the second-generation group.
During the past two to three decades, there has been a trend toward a reduction of the estrogen component (ethinylestradiol) and the search for different and allegedly better progestins. The reduction in estrogen was carried out on the assumption that this was the main culprit for the thrombotic complications.
In the past few years, it has been suggested that progestins may also have a thrombogenic role. This has first been claimed for the so-called third-generation progestins, namely gestoden or desogestrel, which were introduced in the late 1980s or early 1990s and are now widely used (16, 17, 19, 20) . They were claimed to have less androgenic activity and consequently to have a beneficial effect on blood lipids and are particularly useful for women with diabetes mellitus or dyslipidemia or androgenic features.
Several studies have shown that these new progestins, together with 0.03-mg ethynilestradiol are associated with an increased risk of venous thromboembolism as compared with products containing second-generation progestins (e.g., levonorgestrel). The results of these papers have been harshly criticized by many investigators as biased. The discussions were not always serene and balanced and sometimes became even personal (21) (22) (23) (24) (25) (26) (27) . The overall impression that an independent investigator may receive from an accurate evaluation of available data and from his or her experience is that the preparations containing third-generation progestins may be associated with a slightly increased risk of venous thrombosis as compared with products containing second-generation progestins.
The overall incidence of venous thromboembolism during the past decades seems decreased but it is difficult to demonstrate. The higher degree of information that we have today versus 20 or 30 years ago about the thrombogenic role of these compounds may represent a bias. Patients with clotting defects that were not known 20 or 30 years ago are now advised of the danger of taking oral contraceptives. This may also represent a bias. The best association seems to be the one that combines a second-generation progestin, regardless of the dosage, and 0.03-mg ethylnilestradiol. There are at least two such preparations available (Ovranet, Wyeth-Lederle; Egogyn, Schering).
There are also two so-called triphasic preparations (Trigynon, Schering; Trinordiol, Wyeth-Lederle) that could enter this group. The estrogen content is in fact the same, namely 0.03 mg, except for the fact that in one preparation (Trinordiol, Wyeth-Lederle), the second week pills contain 0.04 mg, and the progestins increase in both products from 0.05 mg in the first week to 0.075 mg in the second week to 0.0125 mg in the third week pills. The brand names quoted are those present in Italy. They may vary from one country to the other but the composition of the preparation remains the same.
Finally during 2000 or 2001 two preparations "recycling" levonorgestrel as a progestin together with very low estrogen doses have been introduced. One of these preparations was manufac- tured by a company (Wyeth-Lederle) previously heavily involved in the use of third-generation progestins as a response to the criticism for the purported more evident thrombogenic activity of the latter in comparison with second-generation progestins. The second preparation with a similar composition was introduced by Farmades S.p.A. A preparation containing 28 pills (24 active pills + four placebo) has been introduced recently (Minesse, Wyeth-Lederle). These pills contain a low estrogen dosage, 0.015 mg, but still contain gestodene as progestin. Therefore they should be considered, despite the low estrogen content, as third-generation preparations.
During these past 10 years, we studied 146 consecutive women with manifest venous thrombotic phenomena during oral contraceptive therapy. An analysis of the oral contraceptive being taken by those women at the time of appearance of the venous thromboembolism is gathered in Table 4 .
The large majority of these symptomatic patients with contraceptive-associated side effects were taking preparations containing third-generation progestins. These data do not have an absolute value because we do not know how many women in the general population were taking a given preparation at the time venous thrombosis appeared in some of them. However they may be at least indicative. In fact one may assume, on the basis of a preliminary survey of several pharmacies in the Padua area during these years, that approximately 30% of women have taken preparations containing old or second-generation progestins and the remaining 70% took preparations with third-generation progestins. In other words, it appears that the ratio between new progestins versus old ones was about 2:1. If this is so, it would seem that our results do not confirm the occurrence of more venous thromboembolism manifestations in women taking third-generation products. In fact, the number of women who were taking preparations containing third-generation progestins versus those who were taking preparations with old progestins was about 2 to 1 (Table 4 ), similar to the real proportion of use. Associated congenital or acquired risk factors were approximately equally distributed between the two groups of women. It seems only that venous thrombosis without associated risk factors were slightly more frequent in women taking third-generation progestins (approximately 43% vs. 37.6%). Conversely there were more instances of spontaneous or idiopathic thrombosis in users of third-generation progestins. The differences are not statistically significant, but this could be consistent with the claim that those compounds are somewhat more thrombogenic. This has to be confirmed by an analysis of the number of prescriptions filled in a large sample of pharmacies in the same area where women with venous thrombosis are studied. However it indicates that a careful evaluation of facts and accurate prospective studies are needed to ascertain the accuracy of biologic phenomena.
These conclusions are in no way intended to favor any drug company in comparison to others. In fact, we have no interest in the manufacturers of the preparations that are generally claimed to the safer in terms of venous thrombotic complications. On the basis of available evidence it seems preferable and safe to encourage women to start contraceptive therapy using products that contain second-generation progestins. An exception could be made for women with diabetes mellitus, dyslipidemia, or high androgen levels. In any case it must be the responsibility of the prescribing physician to choose the preparation most suited to a given patient. Because there is a demonstrated increased incidence of venous thrombosis during the first year in unscreened new users, it could be safe to start with a preparation containing second-generation progestins; and then eventually switch to thirdgeneration compounds if necessary.
The increased incidence of venous thrombosis seen in new users is probably due to the fact that these women were not properly screened before starting oral contraceptive therapy. Most of these women who show an early thrombotic complications are probably carriers of a congenital thrombophilic state that is aggravated by the oral contraceptive therapy and a venous thrombosis ensues (5) .
There is no evidence instead for advising women who are already taking medications containing third-generation progestins without any complications to change medication. The difference, if any, is too small to justify switching from one preparation to the other. This is particularly true if one remembers that a careful pre-prescription evaluation of women who are supposed to start oral contraceptive therapy may eliminate substantially or completely the risk of venous thromboembolism. This evaluation should consider the exclusion of women with a family history of idiopathic venous thrombosis, women with a history of venous thrombosis, and women with known congenital prothrombotic clotting defects (28) (29) (30) (31) (32) .
Probably it is not a problem of the type of progestin present in the pill. Every pill is associated with about a fourfold increased risk to develop venous thrombosis with respect to risk in nonusers. Once this is kept in mind it is up to the prescribing physician to evaluate this risk in comparison with other risks such as unwanted pregnancies, elective abortions, psychological distress, etc. The lack of adequate selection could have introduced bias and therefore skewed the results toward one side. This appears to be confirmed by what has been known as the 0.02-mg ethinylestradiol conundrum (14) .
It has been shown in fact that, contrary to the general expectation, women who were taking preparations with the lowest estrogen content, 0.02 mg/pill, with a third-generation progestin showed a higher prevalence of venous thromboembolism. This observation is difficult to explain and casts doubt on the conclusions of those who purported a more thrombogenic effect of preparations that contained third-generation progestins.
